Acute ischemic stroke complicated with nonvalvular atrial fibrillation
Conditions
Interventions
Observation group:Rivaroxaban 20mg/15mg qd po, OR dabigatran etexilate 150mg bid po
Control group:Rivaroxaban 10mg qd po, OR dabigatran etexilate 110mg bid po
Sponsors
Nanjing drum tower hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of the guidelines, and be diagnosed with acute ischemic stroke by head CT or MRI; 2. The electrocardiogram or ambulatory electrocardiogram meets the diagnostic criteria for atrial fibrillation, and there is no rheumatic severe mitral stenosis, prosthetic valve replacement or valve repair surgery; 3. Patients taking rivaroxaban or dabigatran etexilate; 4. The patient can sign the informed consent form; 5. Complete clinical case data and related examination results.
Exclusion criteria
Exclusion criteria: 1. Bleeding disorder or thrombocytopenia (<50×10^9/L) before the use of anticoagulant drugs after the onset of this disease; 2. History of gastrointestinal or urinary tract bleeding in the past 1 month; 3. History of cerebral hemorrhage in the past 3 months; 4. Creatinine clearance < 15 mL/min; 5. Recent combination of drugs that may affect the blood concentration of NOACs, such as antifungal drugs including ketoconazole, itraconazole and fluconazole; 6. Those who switch to other anticoagulant drugs during medication; 7. Patients who are allergic to rivaroxaban and dabigatran etexilate; 8. Patients with incomplete data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mRS score;Clinically relevant major bleeding events;Recurrence ischemic stroke; | — |
Secondary
| Measure | Time frame |
|---|---|
| Myocardial infarction;Systemic embolism;Clinically relevant non-major bleeding events;Non-bleeding adverse events; | — |
Countries
China
Contacts
Public ContactJiang Chenxiao
Nanjing drum tower hospital
Outcome results
None listed